HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma - Courtney, K D; Ma, Y; de Leon, A D (Clin Cancer Res, 2020)
et al.